HIMS Shares Surge 73% Amid Positive Analyst Outlook
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 5 hours ago
0mins
Should l Buy HIMS?
Source: stocktwits
- Stock Surge Drivers: HIMS shares have surged over 73% this week, primarily driven by Barclays' bullish outlook, which raised the price target from $25 to $29, indicating an 8% upside from current levels.
- Legal Uncertainty Lifted: The partnership with Novo Nordisk has removed a key legal uncertainty for HIMS, as Novo dropped its patent infringement lawsuit against the company, further boosting market confidence in HIMS.
- New Product Potential: Barclays highlighted that the market is still underappreciating HIMS' potential from new products, particularly the weight-loss and diabetes drugs Ozempic and Wegovy, which are expected to generate significant new revenue streams for the company.
- Investor Sentiment: Retail sentiment on Stocktwits remains 'extremely bullish' with high message volumes, although some users speculate about a potential stock offering, the overall market sentiment towards HIMS is positive regarding its future performance.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy HIMS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on HIMS
Wall Street analysts forecast HIMS stock price to rise
12 Analyst Rating
3 Buy
6 Hold
3 Sell
Hold
Current: 23.470
Low
16.50
Averages
32.95
High
60.00
Current: 23.470
Low
16.50
Averages
32.95
High
60.00
About HIMS
Hims & Hers Health, Inc. provides a consumer-first platform, which helps customers to fulfill their health and wellness needs. Its platform includes access to a provider network, a clinically focused electronic medical record system, digital prescriptions, cloud pharmacy fulfillment, and personalization capabilities. Its digital platform enables access to treatments for a range of chronic conditions, including those related to sexual health, hair loss, dermatology, mental health, and weight loss. It connects patients to licensed healthcare professionals who can prescribe medications when appropriate and prescriptions are fulfilled online through licensed pharmacies on a subscription basis. It also offers access to a range of health and wellness products designed to meet individual needs, which can include curated prescription and non-prescription products. Through its mobile applications, consumers can access a range of educational programs, wellness content, and other services.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Hims Stock Soars 50% Following Novo Partnership and Legal Settlement
- Stock Surge: Hims & Hers Health Inc. shares have surged nearly 50% since Monday, marking its best week ever, primarily driven by the partnership with Novo Nordisk to offer Ozempic and Wegovy, indicating a strong market rebound for the company.
- Legal Resolution: Novo Nordisk's withdrawal of its patent infringement lawsuit against Hims removes a significant legal overhang, allowing Hims to continue selling compounded GLP-1 drugs, which is expected to further boost sales and enhance market confidence.
- Executive Appointment: Hims has appointed former Eli Lilly communications executive Kathryn Beiser as Chief Communications Officer, responsible for overseeing internal and external communications, reflecting the company's strategic focus on expanding its healthcare platform and enhancing brand image.
- Investor Sentiment Shift: Following the partnership announcement with Novo, investor sentiment has turned extremely bullish, with message volumes on Stocktwits surging over 400%, indicating strong market confidence in Hims' future prospects.
See More
Analysis of the Appeal of Heavily Shorted Stocks
- Short Interest Analysis: Many traders focus on heavily shorted stocks as they are perceived to carry potential downside risks, particularly when companies face challenges like disappointing earnings and persistent cash burn, which could lead to stock price declines.
- Short Squeeze Mechanics: A short squeeze is a rapid, feedback-driven price increase often triggered by unexpected positive catalysts, such as stronger-than-expected earnings or improved guidance, forcing short sellers to cover their positions, which further drives up the stock price.
- Characteristics of Heavily Shorted Stocks: Heavily shorted stocks typically belong to companies with market caps above $2 billion, average 14-day trading volumes exceeding 5 million shares, and free floats above 5 million shares, attracting significant attention from professional traders due to high short interest.
- Market Dynamics Impact: High short interest not only draws the attention of institutional investors but also piques the interest of retail and momentum traders, who believe that once the stock begins to rebound, short sellers will be forced to cover, accelerating the stock price increase.
See More
HIMS Shares Surge 73% Amid Positive Analyst Outlook
- Stock Surge Drivers: HIMS shares have surged over 73% this week, primarily driven by Barclays' bullish outlook, which raised the price target from $25 to $29, indicating an 8% upside from current levels.
- Legal Uncertainty Lifted: The partnership with Novo Nordisk has removed a key legal uncertainty for HIMS, as Novo dropped its patent infringement lawsuit against the company, further boosting market confidence in HIMS.
- New Product Potential: Barclays highlighted that the market is still underappreciating HIMS' potential from new products, particularly the weight-loss and diabetes drugs Ozempic and Wegovy, which are expected to generate significant new revenue streams for the company.
- Investor Sentiment: Retail sentiment on Stocktwits remains 'extremely bullish' with high message volumes, although some users speculate about a potential stock offering, the overall market sentiment towards HIMS is positive regarding its future performance.
See More
Hims & Hers Health Stock Rises on Positive Developments
- Strategic Partnership: Hims & Hers' collaboration with Novo Nordisk introduces FDA-approved weight-loss drugs Ozempic and Wegovy to its platform, marking a significant shift in its weight-loss strategy that is expected to attract more customers and enhance market competitiveness.
- Advertising Strategy Shift: The company is transitioning its U.S. weight-loss business from actively promoting compounded GLP-1 drugs to a broader range of FDA-approved treatments, which not only meets patient needs but also enhances brand image, likely increasing customer trust and loyalty.
- Analyst Upgrades: Following the Novo partnership, Citigroup upgraded Hims stock from Sell to Neutral, raising its price target from $13.25 to $24, indicating increased market confidence in the company's future performance.
- Expanded Member Benefits: Hims & Hers launched a new subscriber benefits program offering discounts on services and products from partners like Prenuvo and Eight Sleep, further broadening its wellness ecosystem, which is expected to attract more users and enhance customer retention.
See More
Serve Robotics Shares Surge After Strong Q4 Results and Upgraded Sales Guidance
- Strong Earnings Report: Serve Robotics reported a fourth-quarter adjusted loss of 34 cents per share, outperforming the expected loss of 53 cents, indicating significant improvements in cost control and operational efficiency, which bolstered investor confidence.
- Sales Performance Exceeds Expectations: The company achieved sales of $882,000, surpassing the consensus estimate of $762,500, demonstrating robust product demand that could drive future revenue growth and enhance market competitiveness.
- Significant Stock Price Increase: Following the positive earnings report, Serve Robotics shares surged 16.2% to $11.24 on Wednesday, reflecting market optimism about the company's future prospects and potentially attracting more investor interest.
- Upgraded Sales Guidance: The company raised its FY26 sales guidance, indicating management's confidence in future performance, which may further drive stock price appreciation and enhance market recognition of its long-term growth potential.
See More
Hims & Hers Appoints New PR Chief Kathryn Beiser
- PR Team Restructuring: Hims & Hers Health has appointed Kathryn Beiser as the new Chief Communications Officer, who previously served five years at Lilly, and her extensive PR experience is expected to enhance the company's brand image and market influence.
- Strategic Shift: Following a partnership with Novo Nordisk, Hims & Hers is adjusting its sales strategy to focus on brand-name obesity drugs, a move that could strengthen its position in a competitive market.
- Leadership Transformation: Beiser emphasized that Hims & Hers fosters a culture of 'collaboration and experimentation,' which is likely to drive positive change and enhance innovation and market responsiveness.
- Executive Support: Hims & Hers CEO Andrew Dudum expressed strong support for Beiser's appointment, stating that her collaboration with the executive team feels like a decade of experience, reflecting confidence and high expectations for the new leadership.
See More
Hims Stock Soars 50% Following Novo Partnership and Legal Settlement
- Stock Surge: Hims & Hers Health Inc. shares have surged nearly 50% since Monday, marking its best week ever, primarily driven by the partnership with Novo Nordisk to offer Ozempic and Wegovy, indicating a strong market rebound for the company.
- Legal Resolution: Novo Nordisk's withdrawal of its patent infringement lawsuit against Hims removes a significant legal overhang, allowing Hims to continue selling compounded GLP-1 drugs, which is expected to further boost sales and enhance market confidence.
- Executive Appointment: Hims has appointed former Eli Lilly communications executive Kathryn Beiser as Chief Communications Officer, responsible for overseeing internal and external communications, reflecting the company's strategic focus on expanding its healthcare platform and enhancing brand image.
- Investor Sentiment Shift: Following the partnership announcement with Novo, investor sentiment has turned extremely bullish, with message volumes on Stocktwits surging over 400%, indicating strong market confidence in Hims' future prospects.
See More
Analysis of the Appeal of Heavily Shorted Stocks
- Short Interest Analysis: Many traders focus on heavily shorted stocks as they are perceived to carry potential downside risks, particularly when companies face challenges like disappointing earnings and persistent cash burn, which could lead to stock price declines.
- Short Squeeze Mechanics: A short squeeze is a rapid, feedback-driven price increase often triggered by unexpected positive catalysts, such as stronger-than-expected earnings or improved guidance, forcing short sellers to cover their positions, which further drives up the stock price.
- Characteristics of Heavily Shorted Stocks: Heavily shorted stocks typically belong to companies with market caps above $2 billion, average 14-day trading volumes exceeding 5 million shares, and free floats above 5 million shares, attracting significant attention from professional traders due to high short interest.
- Market Dynamics Impact: High short interest not only draws the attention of institutional investors but also piques the interest of retail and momentum traders, who believe that once the stock begins to rebound, short sellers will be forced to cover, accelerating the stock price increase.
See More
HIMS Shares Surge 73% Amid Positive Analyst Outlook
- Stock Surge Drivers: HIMS shares have surged over 73% this week, primarily driven by Barclays' bullish outlook, which raised the price target from $25 to $29, indicating an 8% upside from current levels.
- Legal Uncertainty Lifted: The partnership with Novo Nordisk has removed a key legal uncertainty for HIMS, as Novo dropped its patent infringement lawsuit against the company, further boosting market confidence in HIMS.
- New Product Potential: Barclays highlighted that the market is still underappreciating HIMS' potential from new products, particularly the weight-loss and diabetes drugs Ozempic and Wegovy, which are expected to generate significant new revenue streams for the company.
- Investor Sentiment: Retail sentiment on Stocktwits remains 'extremely bullish' with high message volumes, although some users speculate about a potential stock offering, the overall market sentiment towards HIMS is positive regarding its future performance.
See More
Hims & Hers Health Stock Rises on Positive Developments
- Strategic Partnership: Hims & Hers' collaboration with Novo Nordisk introduces FDA-approved weight-loss drugs Ozempic and Wegovy to its platform, marking a significant shift in its weight-loss strategy that is expected to attract more customers and enhance market competitiveness.
- Advertising Strategy Shift: The company is transitioning its U.S. weight-loss business from actively promoting compounded GLP-1 drugs to a broader range of FDA-approved treatments, which not only meets patient needs but also enhances brand image, likely increasing customer trust and loyalty.
- Analyst Upgrades: Following the Novo partnership, Citigroup upgraded Hims stock from Sell to Neutral, raising its price target from $13.25 to $24, indicating increased market confidence in the company's future performance.
- Expanded Member Benefits: Hims & Hers launched a new subscriber benefits program offering discounts on services and products from partners like Prenuvo and Eight Sleep, further broadening its wellness ecosystem, which is expected to attract more users and enhance customer retention.
See More
Serve Robotics Shares Surge After Strong Q4 Results and Upgraded Sales Guidance
- Strong Earnings Report: Serve Robotics reported a fourth-quarter adjusted loss of 34 cents per share, outperforming the expected loss of 53 cents, indicating significant improvements in cost control and operational efficiency, which bolstered investor confidence.
- Sales Performance Exceeds Expectations: The company achieved sales of $882,000, surpassing the consensus estimate of $762,500, demonstrating robust product demand that could drive future revenue growth and enhance market competitiveness.
- Significant Stock Price Increase: Following the positive earnings report, Serve Robotics shares surged 16.2% to $11.24 on Wednesday, reflecting market optimism about the company's future prospects and potentially attracting more investor interest.
- Upgraded Sales Guidance: The company raised its FY26 sales guidance, indicating management's confidence in future performance, which may further drive stock price appreciation and enhance market recognition of its long-term growth potential.
See More
Hims & Hers Appoints New PR Chief Kathryn Beiser
- PR Team Restructuring: Hims & Hers Health has appointed Kathryn Beiser as the new Chief Communications Officer, who previously served five years at Lilly, and her extensive PR experience is expected to enhance the company's brand image and market influence.
- Strategic Shift: Following a partnership with Novo Nordisk, Hims & Hers is adjusting its sales strategy to focus on brand-name obesity drugs, a move that could strengthen its position in a competitive market.
- Leadership Transformation: Beiser emphasized that Hims & Hers fosters a culture of 'collaboration and experimentation,' which is likely to drive positive change and enhance innovation and market responsiveness.
- Executive Support: Hims & Hers CEO Andrew Dudum expressed strong support for Beiser's appointment, stating that her collaboration with the executive team feels like a decade of experience, reflecting confidence and high expectations for the new leadership.
See More
